Silo Pharma announced that its wholly owned subsidiary, QwikAgents, has engaged Caylent, an Amazon Web Services (AWS) Premier Tier Services Partner, to design and build an AWS-native QwikAgents platform. The collaboration, announced on August 06, 2026, aims to advance the enterprise AI platform by preserving QwikAgents' core functionality while enhancing scalability, performance, and security for enterprise deployment and future product innovation. Rather than migrating the existing application, Caylent will build a new AWS-native foundation. The engagement is structured to align with AWS funding programs, with funding support expected from AWS and Caylent. Eric Weisblum, Chief Executive Officer of Silo Pharma, said the collaboration is an important step in positioning QwikAgents for enterprise growth, combining the AI platform with Caylent's AWS expertise to create a scalable foundation for commercialization and innovation. QwikAgents is a managed AI agent platform delivering autonomous agents for research, content generation, scheduling, and workflow automation. Silo Pharma is a developmental-stage biopharmaceutical company focused on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.